145 related articles for article (PubMed ID: 11555670)
1. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13.
Bernard J; Treton D; Vermot-Desroches C; Boden C; Horellou P; Angevin E; Galanaud P; Wijdenes J; Richard Y
Lab Invest; 2001 Sep; 81(9):1223-31. PubMed ID: 11555670
[TBL] [Abstract][Full Text] [Related]
2. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.
Madhankumar AB; Mintz A; Debinski W
Neoplasia; 2004; 6(1):15-22. PubMed ID: 15068667
[TBL] [Abstract][Full Text] [Related]
5. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
6. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
7. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine.
Madhankumar AB; Mintz A; Debinski W
J Biol Chem; 2002 Nov; 277(45):43194-205. PubMed ID: 12189139
[TBL] [Abstract][Full Text] [Related]
8. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.
Debinski W; Gibo DM
Mol Med; 2000 May; 6(5):440-9. PubMed ID: 10952023
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.
Malabarba MG; Rui H; Deutsch HH; Chung J; Kalthoff FS; Farrar WL; Kirken RA
Biochem J; 1996 Nov; 319 ( Pt 3)(Pt 3):865-72. PubMed ID: 8920992
[TBL] [Abstract][Full Text] [Related]
10. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
Debinski W; Miner R; Leland P; Obiri NI; Puri RK
J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406
[TBL] [Abstract][Full Text] [Related]
11. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.
Zhou G; Roizman B
J Virol; 2005 May; 79(9):5272-7. PubMed ID: 15827141
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.
Nash KT; Thompson JP; Debinski W
Crit Rev Oncol Hematol; 2001; 39(1-2):87-98. PubMed ID: 11418305
[TBL] [Abstract][Full Text] [Related]
14. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
15. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
16. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
17. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
18. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
19. IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway.
Kang MA; Lee J; Lee CM; Park HS; Jang KY; Park SH
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33917914
[TBL] [Abstract][Full Text] [Related]
20. The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor alpha2.
Feng N; Lugli SM; Schnyder B; Gauchat JF; Graber P; Schlagenhauf E; Schnarr B; Wiederkehr-Adam M; Duschl A; Heim MH; Lutz RA; Moser R
Lab Invest; 1998 May; 78(5):591-602. PubMed ID: 9605184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
